menu
    • menu
    [{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Glepaglutide","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Glepaglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank A\/S","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2022","type":"Private Placement","leadProduct":"Glepaglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Zealand Pharma \/ Danske Bank A\/S","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank A\/S"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2022","type":"Private Placement","leadProduct":"Glepaglutide","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Glepaglutide","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Glepaglutide

    Menu

    Glepaglutide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zealand Pharma

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            Zealand Pharma

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glepaglutide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zealand Pharma Submits New Drug Application to the US FDA for Glepaglutide in Short Bowel Syndrome

                            Details : ZP1848 (glepaglutide) is a long-acting GLP-2 analog synthetic peptide, which is currently being evaluated for the treatment of patients with short bowel syndrome.

                            Brand Name : ZP1848

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            December 22, 2023

                            Lead Product(s) : Glepaglutide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zealand Pharma

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            Zealand Pharma

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glepaglutide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Danske Bank A/S

                            Deal Size : $102.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Zealand Pharma Announces Completion of a Directed Issue and Private Placement of 4,975,000 New Ordinary Shares...

                            Details : The net proceeds from the offering are intended to support the Phase 3 EASE clinical program for glepaglutide (ZP1848) and potential regulatory submission for SBS, and pursue a strong strategic partner for future commercialization.

                            Brand Name : ZP1848

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            October 04, 2022

                            Lead Product(s) : Glepaglutide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Danske Bank A/S

                            Deal Size : $102.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zealand Pharma

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            Zealand Pharma

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glepaglutide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Danske Bank

                            Deal Size : Undisclosed

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Zealand Pharma Announces Directed Issue And Private Placement Of Approximately 4.5M New Shares

                            Details : The net proceeds from the offering are intended to support the Phase 3 EASE clinical program for glepaglutide (ZP1848) and potential regulatory submission for SBS, and pursue a strong strategic partner for future commercialization.

                            Brand Name : ZP1848

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            October 04, 2022

                            Lead Product(s) : Glepaglutide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Danske Bank

                            Deal Size : Undisclosed

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zealand Pharma

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            Zealand Pharma

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glepaglutide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short ...

                            Details : Phase 3 trial (EASE-SBS 1) enrollment completed for ZP1848 (glepaglutide), a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome. Full trial results of EASE-SBS 1 expected in the third quarter of 2022.

                            Brand Name : ZP1848

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            January 20, 2022

                            Lead Product(s) : Glepaglutide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zealand Pharma

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Zealand Pharma

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glepaglutide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zealand Pharma to Present Data on Glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Trans...

                            Details : The pivotal trial is a randomized, double-blind and placebo-controlled study, with both once- and twice-weekly dosing regimens. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for glepaglutide for the treatment of SBS.

                            Brand Name : ZP1848

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 29, 2021

                            Lead Product(s) : Glepaglutide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth